ReNeuron Group PLC on Friday said it presented positive new data at a leading summit of targeted therapies.

Shares in the Bridgend, Wales-based stem cell and exosomes technology company were trading 7.3% higher at 27.90 pence each in London on Friday morning.

At the summit, held in Boston, Massachusetts, the company’s Chief Scientific Officer Randolph Corteling highlighted the ‘significant advantages of the company’s stem cell derived exosome approach.’

An exosome is a small ‘sac-like structure’ formed inside a cell. It contains some of the cell’s proteins, DNA and RNA. Exosomes may play a role in the spread of cancer and may keep immune cells from killing cancer cells.

The company presented evidence that said its CustomEx exosome types ‘outperformed’ the conventional approach by a minimum of a 10-fold in each of the three different cell types.

The best performing CustomEx exosome type showed a 600% improvement in siRNA delivery to the target cell when compared to delivery from a conventional types of exosomes. siRNA are double-stranded RNA molecules that are thought to offer new opportunities for therapeutic intervention because they act inside the cell to reduce protein expression.

‘The key to the challenge of drug delivery is about getting the chosen payload to the target cell of choice,’ Chief Executive Officer Catherine Isted commented. ‘This data clearly shows how our customisable Exosomes platform CustomExTM, is able to be an enabler for this exciting next generation of targeted therapies.

CSO Corteling stated: ’This represents a significant advance in the potential use of human stem cell-derived exosomes as delivery vectors for complex drug modalities, with this new data highlighting the significant improvement in uptake and delivery of a payload that can be achieved by customising the exosome type to maximise payload delivery to the desired cell type.‘

Copyright 2022 Alliance News Limited. All Rights Reserved.